Compare Alliant Energy Corporation (LNT) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alliant Energy Corporation vs TG Therapeutics Inc — how do they compare? Alliant Energy Corporation trades at $65.85 (market cap $16.99B), while TG Therapeutics Inc trades at $55.24 (market cap $8.16B). The key difference: Alliant Energy Corporation is far larger — about 2.1× TG Therapeutics Inc's market cap, and Alliant Energy Corporation pays a 3.27% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Alliant Energy Corporation for 64 Days and TG Therapeutics Inc for 16 Days on average.
| LNT | TGTX | |
|---|---|---|
Market Cap | $16.99B | $8.16B |
Volume | 2,488,387 | 1,735,121 |
Sector | Utilities | Health |
52-Week High | $78.03 | $59.06 |
52-Week Low | $63.21 | $26.94 |
Typical Hold Time | 64 Days | 16 Days |
Enterprise Value | $29.08B | $8.37B |
Dividend Yield | 3.27% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LNT trades at $65.84, up 0.97% today, with a mixed technical picture showing bullish overall signals but bearish moving averages. The company reported strong earnings beats in recent quarters and maintains solid profitability with an 18.45% net margin. Analyst consensus is bullish with a $77 price target, and institutional interest remains high, evidenced by recent large purchases.
LNT's outlook is supported by a $13.4 billion capital investment plan and growing data center demand, though rising debt levels and competitive pressures present risks. The stock offers a defensive income stream with a consistent dividend, but investors should monitor execution of growth initiatives amid economic uncertainty.
TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.
The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Alliant Energy Corporation
Alliant Energy is the parent of two regulated utilities, Interstate Power and Light and Wisconsin Power and Light, serving nearly 1 million electricity and natural gas customers and approximately 420,000 natural gas-only customers. Both subsidiaries engage in the generation and distribution of electricity and the distribution and transportation of natural gas. Alliant also owns a 16% interest in American Transmission Co.
Read more on LNT →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
